Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Shire_plc
2016 |
| gptkbp:awards |
various industry awards
|
| gptkbp:businessModel |
patient-centric approach
|
| gptkbp:CEO |
gptkb:M._Christine_Carr
|
| gptkbp:clinicalTrials |
ongoing
collaborative studies |
| gptkbp:communityEngagement |
healthcare_initiatives
|
| gptkbp:employees |
approximately 16,000
|
| gptkbp:focusesOn |
oncology
rare diseases chronic conditions hematology hemophilia therapeutics immunology |
| gptkbp:founded |
2015
|
| gptkbp:funding |
$8.5 billion (2015)
|
| gptkbp:globalPresence |
operates in over 100 countries
|
| gptkbp:headCoach |
16,000 (2015)
|
| gptkbp:headquarters |
gptkb:Bannockburn,_Illinois
|
| https://www.w3.org/2000/01/rdf-schema#label |
Baxalta Incorporated
|
| gptkbp:innovation |
focus on patient care
|
| gptkbp:investmentFocus |
biopharmaceutical research
|
| gptkbp:leadership |
diverse management team
|
| gptkbp:manufacturer |
gptkb:Bannockburn,_Illinois
|
| gptkbp:market |
$30 billion (2015)
|
| gptkbp:netIncome |
$1.1 billion (2015)
|
| gptkbp:operatingHours |
$1.3 billion (2015)
|
| gptkbp:parentCompany |
gptkb:Shire_plc
|
| gptkbp:partnerships |
multiple academic institutions
various biotech companies |
| gptkbp:philanthropy |
support for patient organizations
|
| gptkbp:products |
gptkb:Vonvendi
Advate Feiba Hyate_C |
| gptkbp:regulatoryCompliance |
FDA_approved_products
|
| gptkbp:researchAndDevelopment |
$600 million (2015)
|
| gptkbp:revenue |
$4.5 billion (2015)
|
| gptkbp:specializesIn |
biologics
|
| gptkbp:stockSymbol |
BXLT
|
| gptkbp:strategicGoals |
improve patient outcomes
increase market share drive innovation expand product portfolio enhance global reach |
| gptkbp:subsidiary |
gptkb:Baxalta_US_Inc.
|
| gptkbp:sustainability |
environmental responsibility
|
| gptkbp:tradedOn |
gptkb:NYSE
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.baxalta.com
|